CN103748074B - 芳氧基喹啉类衍生物及其治疗用途 - Google Patents
芳氧基喹啉类衍生物及其治疗用途 Download PDFInfo
- Publication number
- CN103748074B CN103748074B CN201280028921.8A CN201280028921A CN103748074B CN 103748074 B CN103748074 B CN 103748074B CN 201280028921 A CN201280028921 A CN 201280028921A CN 103748074 B CN103748074 B CN 103748074B
- Authority
- CN
- China
- Prior art keywords
- methoxyl group
- phenyl
- oxygen base
- diformamide
- quinolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(CN1CCC(COc2cc3nccc(Oc(cc4)ccc4NC(C4(CC4)C(Nc4cc(F)ccc4)=O)=O)c3cc2OC)CC1)=O Chemical compound C*C(CN1CCC(COc2cc3nccc(Oc(cc4)ccc4NC(C4(CC4)C(Nc4cc(F)ccc4)=O)=O)c3cc2OC)CC1)=O 0.000 description 1
- IERHKRBARYJACD-VZUCSPMQSA-N C/C(/COc1cc2nccc(Cl)c2cc1OC)=C\C=C Chemical compound C/C(/COc1cc2nccc(Cl)c2cc1OC)=C\C=C IERHKRBARYJACD-VZUCSPMQSA-N 0.000 description 1
- DQCPAQBTQJWOKC-UHFFFAOYSA-N CC(C)(C(Nc(cc1)cc(F)c1Oc1c(cc(c(OCC2CCN(CC(NC)=O)CC2)c2)OC)c2ncc1)=O)C(Nc(cc1)cc(Cl)c1F)=O Chemical compound CC(C)(C(Nc(cc1)cc(F)c1Oc1c(cc(c(OCC2CCN(CC(NC)=O)CC2)c2)OC)c2ncc1)=O)C(Nc(cc1)cc(Cl)c1F)=O DQCPAQBTQJWOKC-UHFFFAOYSA-N 0.000 description 1
- UWCGZQMGUWZVNN-UHFFFAOYSA-N COc(c(OCC1CCN(CCS(C)(=O)=O)CC1)cc1ncc2)cc1c2Oc(ccc(NC(C1(CC1)C(Nc1ccccc1)=O)=O)c1)c1F Chemical compound COc(c(OCC1CCN(CCS(C)(=O)=O)CC1)cc1ncc2)cc1c2Oc(ccc(NC(C1(CC1)C(Nc1ccccc1)=O)=O)c1)c1F UWCGZQMGUWZVNN-UHFFFAOYSA-N 0.000 description 1
- MOJNYZNHNHQBLS-UHFFFAOYSA-N Cc(c(F)c1)ccc1NC(C1(CC1)C(Nc(cc1)cc(F)c1Oc1c(cc(c(OCC2CCN(CC(NC)=O)CC2)c2)OC)c2ncc1)=O)=O Chemical compound Cc(c(F)c1)ccc1NC(C1(CC1)C(Nc(cc1)cc(F)c1Oc1c(cc(c(OCC2CCN(CC(NC)=O)CC2)c2)OC)c2ncc1)=O)=O MOJNYZNHNHQBLS-UHFFFAOYSA-N 0.000 description 1
- IYZHHFWPZIOBSX-UHFFFAOYSA-N Cc1cccc(Cl)c1NC(C1(CC1)C(Nc(cc1)cc(F)c1Oc1c(cc(c(OC2CCN(CC(NC)=O)CC2)c2)OC)c2ncc1)=O)=O Chemical compound Cc1cccc(Cl)c1NC(C1(CC1)C(Nc(cc1)cc(F)c1Oc1c(cc(c(OC2CCN(CC(NC)=O)CC2)c2)OC)c2ncc1)=O)=O IYZHHFWPZIOBSX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280028921.8A CN103748074B8 (zh) | 2011-06-17 | 2012-06-15 | 芳氧基喹啉类衍生物及其治疗用途 |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110163215.1 | 2011-06-17 | ||
CN2011101632151 | 2011-06-17 | ||
CN201110163215 | 2011-06-17 | ||
CN2011102520350 | 2011-08-30 | ||
CN201110252035 | 2011-08-30 | ||
CN201110252035.0 | 2011-08-30 | ||
CN2011103971422 | 2011-12-05 | ||
CN201110397142 | 2011-12-05 | ||
CN201110397142.2 | 2011-12-05 | ||
CN201280028921.8A CN103748074B8 (zh) | 2011-06-17 | 2012-06-15 | 芳氧基喹啉类衍生物及其治疗用途 |
PCT/CN2012/077016 WO2012171487A1 (zh) | 2011-06-17 | 2012-06-15 | 芳氧基喹啉类衍生物及其治疗用途 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN103748074A CN103748074A (zh) | 2014-04-23 |
CN103748074B true CN103748074B (zh) | 2016-05-18 |
CN103748074B8 CN103748074B8 (zh) | 2016-09-14 |
Family
ID=47356551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280028921.8A Active CN103748074B8 (zh) | 2011-06-17 | 2012-06-15 | 芳氧基喹啉类衍生物及其治疗用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103748074B8 (zh) |
WO (1) | WO2012171487A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018026877A1 (en) | 2016-08-05 | 2018-02-08 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
CN107778285A (zh) * | 2016-08-24 | 2018-03-09 | 南昌弘益药业有限公司 | 一类喹啉类新化合物 |
CN107778287A (zh) * | 2016-08-26 | 2018-03-09 | 南昌弘益药业有限公司 | 作为酪氨酸蛋白激酶抑制剂的一类化合物 |
CN108329298A (zh) * | 2017-01-17 | 2018-07-27 | 南昌弘益药业有限公司 | 一类喹啉类新化合物制备方法 |
CN108623565A (zh) * | 2017-03-23 | 2018-10-09 | 南昌弘益药业有限公司 | 一种化合物的制备方法 |
CN109824587A (zh) * | 2017-11-23 | 2019-05-31 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂xjf007及其中间体的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102093421A (zh) * | 2011-01-28 | 2011-06-15 | 广州盈升生物科技有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
CN102408411A (zh) * | 2011-09-19 | 2012-04-11 | 广州盈升生物科技有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010229147B2 (en) * | 2009-03-21 | 2012-07-05 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
-
2012
- 2012-06-15 WO PCT/CN2012/077016 patent/WO2012171487A1/zh active Application Filing
- 2012-06-15 CN CN201280028921.8A patent/CN103748074B8/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102093421A (zh) * | 2011-01-28 | 2011-06-15 | 广州盈升生物科技有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
CN102408411A (zh) * | 2011-09-19 | 2012-04-11 | 广州盈升生物科技有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103748074A (zh) | 2014-04-23 |
WO2012171487A1 (zh) | 2012-12-20 |
CN103748074B8 (zh) | 2016-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103748074B (zh) | 芳氧基喹啉类衍生物及其治疗用途 | |
ES2543320T3 (es) | Acetamidas sustituídas con N-(hetero)aril,2-(hetero)arilo para uso como moduladores de señalización de Wnt | |
TWI725266B (zh) | Fgfr4抑制劑、其製備方法與藥學上的應用 | |
WO2022082876A1 (zh) | 靶向蛋白降解c-Met降解剂及其制备方法与应用 | |
TWI462927B (zh) | 對於蛋白質激酶具有抑制活性之噻吩并[3,2-d]嘧啶衍生物 | |
ES2502941T3 (es) | Método de preparación de compuestos de amida de dihidroindeno, las composiciones farmacéuticas que contienen dichos compuestos y el uso como inhibidor de proteína quinasas | |
JP6959663B2 (ja) | Fgfr阻害剤としての複素環化合物 | |
CN102643268B (zh) | 喹啉类及噌啉类化合物及其应用 | |
CN102977014B (zh) | 新的喹啉类化合物及其用途 | |
CN102239150A (zh) | 作为用于增殖性疾病治疗的蛋白激酶抑制剂的新型吲唑衍生物或其药学上可接受的盐以及含有其作为活性成分的药物组合物 | |
CN104211686A (zh) | 喹啉类衍生物及其治疗用途 | |
JP2016518328A (ja) | 癌治療のための化合物 | |
CN103570625A (zh) | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 | |
CN101506214A (zh) | 作为parp抑制剂的吡唑并喹唑啉酮 | |
CN103130792A (zh) | 一种2-氨基噻唑类化合物 | |
CN104119317A (zh) | 含1,2,3-三氮唑的喹啉类化合物及其制备方法和应用 | |
CN104072480A (zh) | 喹啉类化合物及其制备方法和应用 | |
CN106478621B (zh) | 喹啉或喹唑啉类衍生物、制备方法及其应用 | |
CN103467456A (zh) | 3,5-二取代吲哚酮类衍生物及其制备方法和应用 | |
WO2023279938A1 (zh) | 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用 | |
JP2015522607A (ja) | プロテインキナーゼに対する阻害活性を有するイソキノリン−5−カルボキサミド誘導体 | |
CN102633812B (zh) | 噁唑酮并喹唑啉衍生物、制备方法及用途 | |
WO2019223766A1 (zh) | 一种fgfr抑制剂、其制备方法和在药学上的应用 | |
KR20180094880A (ko) | 5원 헤테로시클릭 아미드계 wnt 경로 억제제 | |
CN103396417A (zh) | 新型羟肟酸衍生物及其医疗应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Wenyan Inventor after: Zhao Yan Inventor after: Xu Jun Inventor after: Peng Hong Inventor after: Tao Lin Inventor after: Zhang Xiaoli Inventor after: Zhao Yinying Inventor after: Wang Xiaoxia Inventor after: Li Yonghua Inventor after: Zou Yang Inventor before: Chen Congxi |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160513 Address after: 330096 No. 789 torch street, hi tech Zone, Jiangxi, Nanchang Patentee after: Nanchang Helioeast Pharmaceutical Co., Ltd. Patentee after: TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD. Address before: 300457, Tianjin Binhai New Area, Tianjin Development Zone, Fourth Avenue, No. 80, Tian Da Science and Technology Park, A1 building, room 219, room two Patentee before: TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD. |
|
C53 | Correction of patent for invention or patent application | ||
CI01 | Correction of invention patent gazette |
Correction item: Patentee|Address|Patentee|Inventor Correct: Nanchang helioeast Pharmaceutical Co. Ltd. |Jiangxi 330096 Nanchang torch hi tech Zone Street No. 789|TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD.|Zhang Wenyan|Xu Jun|Peng Hong|Tao Lin|Zhang Xiaoli|Zhao Yinying|Wang Xiaoxia|Li Yonghua|Zou Yang|Zhao Yan False: Tianjin Longbo Gene Medicine Technology Co. Ltd. |Tianjin 300457 city of Tianjin Binhai New Area Development Zone Fourth Street No. 80 Big Science Park A1 building two room 219|Chen Congxi Number: 20 Volume: 32 |
|
CI03 | Correction of invention patent |
Correction item: Patentee|Address|Patentee|Inventor Correct: Nanchang helioeast Pharmaceutical Co. Ltd. |Jiangxi 330096 Nanchang torch hi tech Zone Street No. 789|TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD.|Zhang Wenyan|Xu Jun|Peng Hong|Tao Lin|Zhang Xiaoli|Zhao Yinying|Wang Xiaoxia|Li Yonghua|Zou Yang|Zhao Yan False: Tianjin Longbo Gene Medicine Technology Co. Ltd.| Tianjin 300457 city of Tianjin Binhai New Area Development Zone Fourth Street No. 80 Big Science Park A1 building two room 219|Chen Congxi Number: 20 Page: The title page Volume: 32 |
|
ERR | Gazette correction |